$PALI
PALISADE BIO, INC.

2021 Q4 Form 10-Q Financial Statement

#000095017021004398 Filed on November 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.227M $2.392M $3.990M
YoY Change -19.12% 27.23% 191.24%
% of Gross Profit
Research & Development $800.0K $624.0K $410.0K
YoY Change 95.12% 33.9% -46.75%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $10.00K
YoY Change -100.0% -100.0% -66.67%
% of Gross Profit
Operating Expenses $4.027M $3.016M $4.400M
YoY Change -8.48% 66.08% 105.61%
Operating Profit -$3.016M
YoY Change 66.08%
Interest Expense $5.089M $26.00K -$20.00K
YoY Change -25545.0% -7.14% -122.22%
% of Operating Profit
Other Income/Expense, Net $11.00K $11.10M $0.00
YoY Change -41222.22%
Pretax Income $1.073M $8.087M -$4.420M
YoY Change -124.28% -448.58% 116.67%
Income Tax
% Of Pretax Income
Net Earnings $1.073M $8.087M -$4.420M
YoY Change -124.28% -538.8% 116.67%
Net Earnings / Revenue
Basic Earnings Per Share $0.42
Diluted Earnings Per Share $79.29K $0.42 -$1.529M
COMMON SHARES
Basic Shares Outstanding 13.57M 12.10M 17.30M
Diluted Shares Outstanding 12.11M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.50M $14.10M $10.53M
YoY Change -0.33% 11.49% 106.07%
Cash & Equivalents $10.50M $14.10M $713.0K
Short-Term Investments
Other Short-Term Assets $1.879M $1.988M $2.240M
YoY Change -16.12% -14.68% 339.22%
Inventory
Prepaid Expenses $1.400M
Receivables $0.00 $0.00 $59.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $12.37M $16.09M $896.0K
YoY Change 1281.03% 7.34% -84.13%
LONG-TERM ASSETS
Property, Plant & Equipment $3.000K $3.000K $5.000K
YoY Change -40.0% -80.05% -87.82%
Goodwill
YoY Change
Intangibles $147.1K
YoY Change -78.0%
Long-Term Investments
YoY Change
Other Assets $26.00K $26.00K $10.00K
YoY Change 160.0% 160.0% -95.65%
Total Long-Term Assets $138.0K $182.0K $2.123M
YoY Change -93.5% 2.19% 126.57%
TOTAL ASSETS
Total Short-Term Assets $12.37M $16.09M $896.0K
Total Long-Term Assets $138.0K $182.0K $2.123M
Total Assets $12.51M $16.27M $3.019M
YoY Change 314.44% 7.28% -54.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.323M $1.383M $2.537M
YoY Change -47.85% 138.45% 209.39%
Accrued Expenses $463.0K $722.0K $2.740M
YoY Change -83.1% 415.71% 1857.14%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $87.00K $568.0K $1.047M
YoY Change -91.69%
Total Short-Term Liabilities $2.496M $2.920M $8.082M
YoY Change -69.12% 191.38% 559.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $94.00K
YoY Change -100.0%
Other Long-Term Liabilities $2.651M $9.434M $80.00K
YoY Change 3213.75% 23485.0% -65.22%
Total Long-Term Liabilities $0.00 $0.00 $94.00K
YoY Change -100.0% -100.0% -59.13%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.496M $2.920M $8.082M
Total Long-Term Liabilities $0.00 $0.00 $94.00K
Total Liabilities $5.147M $12.35M $10.12M
YoY Change -49.13% 1079.86% 594.01%
SHAREHOLDERS EQUITY
Retained Earnings $94.60M -$95.70M -$68.03M
YoY Change -239.06% -59.07% -69.35%
Common Stock $143.0K $130.0K $28.00K
YoY Change 410.71% -24.84% -27.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.365M $3.920M -$16.60M
YoY Change
Total Liabilities & Shareholders Equity $12.51M $16.27M $3.019M
YoY Change 314.44% 7.28% -54.15%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q4
OPERATING ACTIVITIES
Net Income $1.073M $8.087M -$4.420M
YoY Change -124.28% -538.8% 116.67%
Depreciation, Depletion And Amortization $0.00 $0.00 $10.00K
YoY Change -100.0% -100.0% -66.67%
Cash From Operating Activities -$3.055M -$2.746M -$2.200M
YoY Change 38.86% -10.84% 7.32%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 -$348.0K
YoY Change
Cash From Investing Activities $0.00 -$348.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -554.0K 4.545M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -3.055M -2.746M -2.200M
Cash From Investing Activities 0.000 -348.0K
Cash From Financing Activities -554.0K 4.545M 0.000
Net Change In Cash -3.609M 1.451M -2.200M
YoY Change 64.05% -147.11% 0.46%
FREE CASH FLOW
Cash From Operating Activities -$3.055M -$2.746M -$2.200M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001357459
pali Acquisition Related Fair Value Change In Warrant Liability Assumed In Merger
AcquisitionRelatedFairValueChangeInWarrantLiabilityAssumedInMerger
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2020Q3 us-gaap Dilutive Securities
DilutiveSecurities
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y1M6D
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Interest Paid Net
InterestPaidNet
CY2021Q3 us-gaap Dilutive Securities
DilutiveSecurities
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Dilutive Securities
DilutiveSecurities
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-33672
dei Entity Registrant Name
EntityRegistrantName
PALISADE BIO, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
52-2007292
dei Entity Address Address Line1
EntityAddressAddressLine1
5800 Armada Drive, Suite 210
dei Entity Address City Or Town
EntityAddressCityOrTown
Carlsbad
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92008
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
704-4900
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
722000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2740000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
89000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1590000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
158000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
168000
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
59000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1988000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
124000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
16092000
CY2021Q3 pali Long Term Debt Current Maturities Excluding Related Party Debt
LongTermDebtCurrentMaturitiesExcludingRelatedPartyDebt
387000
CY2020Q4 pali Long Term Debt Current Maturities Excluding Related Party Debt
LongTermDebtCurrentMaturitiesExcludingRelatedPartyDebt
578000
CY2021Q3 pali Long Term Debt Related Party Current Maturities
LongTermDebtRelatedPartyCurrentMaturities
181000
CY2020Q4 pali Long Term Debt Related Party Current Maturities
LongTermDebtRelatedPartyCurrentMaturities
469000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2920000
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
dei Trading Symbol
TradingSymbol
PALI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13574049
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14104000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
713000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
896000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2021Q3 pali Deferred Merger Transaction Costs
DeferredMergerTransactionCosts
0
CY2020Q4 pali Deferred Merger Transaction Costs
DeferredMergerTransactionCosts
1817000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
153000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
275000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5000
CY2021Q3 us-gaap Assets
Assets
16274000
CY2020Q4 us-gaap Assets
Assets
3019000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1383000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2537000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8082000
CY2021Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
9434000
CY2020Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1830000
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
94000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-16602000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
112000
CY2021Q3 us-gaap Liabilities
Liabilities
12354000
CY2020Q4 us-gaap Liabilities
Liabilities
10118000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
6797500
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12929911
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12929911
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2774501
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2774501
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
130000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
28000
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
99503000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
51396000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-95715000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-68026000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
3920000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16274000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3019000
CY2021Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
624000
CY2020Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
412000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1630000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2314000
CY2021Q3 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
CY2020Q3 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
30117000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2392000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1404000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6080000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3738000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
3016000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
1816000
us-gaap Operating Expenses
OperatingExpenses
37827000
us-gaap Operating Expenses
OperatingExpenses
6052000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3016000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1816000
us-gaap Operating Income Loss
OperatingIncomeLoss
-37827000
us-gaap Operating Income Loss
OperatingIncomeLoss
-6052000
CY2021Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2020Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
279000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2021Q3 pali Loss On Issuance Of Secured Debt
LossOnIssuanceOfSecuredDebt
0
CY2020Q3 pali Loss On Issuance Of Secured Debt
LossOnIssuanceOfSecuredDebt
0
pali Loss On Issuance Of Secured Debt
LossOnIssuanceOfSecuredDebt
686000
pali Loss On Issuance Of Secured Debt
LossOnIssuanceOfSecuredDebt
0
CY2021Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
12764000
CY2020Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
17939000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
CY2021Q3 pali Gain Loss From Change In Fair Value Of Share Liability
GainLossFromChangeInFairValueOfShareLiability
18000
CY2020Q3 pali Gain Loss From Change In Fair Value Of Share Liability
GainLossFromChangeInFairValueOfShareLiability
0
pali Gain Loss From Change In Fair Value Of Share Liability
GainLossFromChangeInFairValueOfShareLiability
91000
pali Gain Loss From Change In Fair Value Of Share Liability
GainLossFromChangeInFairValueOfShareLiability
0
CY2021Q3 us-gaap Interest Expense
InterestExpense
26000
CY2020Q3 us-gaap Interest Expense
InterestExpense
28000
us-gaap Interest Expense
InterestExpense
2393000
us-gaap Interest Expense
InterestExpense
39000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
20000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
36000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13000
CY2021Q3 pali Loss On Issuance Of Preferred Stock
LossOnIssuanceOfPreferredStock
0
CY2020Q3 pali Loss On Issuance Of Preferred Stock
LossOnIssuanceOfPreferredStock
0
pali Loss On Issuance Of Preferred Stock
LossOnIssuanceOfPreferredStock
1881000
pali Loss On Issuance Of Preferred Stock
LossOnIssuanceOfPreferredStock
0
CY2021Q3 pali Financing Cost Derivative Warrant Liabilities
FinancingCostDerivativeWarrantLiabilities
1673000
CY2020Q3 pali Financing Cost Derivative Warrant Liabilities
FinancingCostDerivativeWarrantLiabilities
0
pali Financing Cost Derivative Warrant Liabilities
FinancingCostDerivativeWarrantLiabilities
3247000
pali Financing Cost Derivative Warrant Liabilities
FinancingCostDerivativeWarrantLiabilities
0
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11103000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-27000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10138000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-26000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
8087000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-1843000
us-gaap Net Income Loss
NetIncomeLoss
-27689000
us-gaap Net Income Loss
NetIncomeLoss
-6078000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.42
pali Adjustments To Additional Paid In Capital Equity Warrant Put Rights Activated Upon Merger
AdjustmentsToAdditionalPaidInCapitalEquityWarrantPutRightsActivatedUponMerger
-51000
pali Adjustments To Additional Paid In Capital Expiration Of Put Rights On Equity Classified Warrants
AdjustmentsToAdditionalPaidInCapitalExpirationOfPutRightsOnEquityClassifiedWarrants
26000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1208000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
16000
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
28728000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2774237
pali Stock Acquired During Period Value
StockAcquiredDuringPeriodValue
2000
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.50
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.19
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.42
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.19
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12100292
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2774502
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7902104
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2774237
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12106771
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2774502
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7952998
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
5118000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1843000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-27689000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6078000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
5119000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-1843000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-32808000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6078000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-9444000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
8087000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
103000
CY2021Q3 pali Conversion Of Share Liability To Common Stock
ConversionOfShareLiabilityToCommonStock
33000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
3920000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-11678000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-1843000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
10000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
664000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-12847000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-16602000
us-gaap Net Income Loss
NetIncomeLoss
-27689000
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1184000
pali Conversion Of Share Liability To Common Stock
ConversionOfShareLiabilityToCommonStock
33000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
3920000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-8332000
us-gaap Net Income Loss
NetIncomeLoss
-6078000
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
9000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
10000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1544000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-12847000
us-gaap Net Income Loss
NetIncomeLoss
-27689000
us-gaap Net Income Loss
NetIncomeLoss
-6078000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
30117000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
pali Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities Noncash Transaction Costs Shared With Acquiree
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesNoncashTransactionCostsSharedWithAcquiree
-135000
pali Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities Noncash Transaction Costs Shared With Acquiree
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesNoncashTransactionCostsSharedWithAcquiree
0
pali Noncash Lease Expense
NoncashLeaseExpense
122000
pali Noncash Lease Expense
NoncashLeaseExpense
105000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
279000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Accretion Expense
AccretionExpense
2334000
us-gaap Accretion Expense
AccretionExpense
32000
pali Loss On Issuance Of Preferred Stock
LossOnIssuanceOfPreferredStock
1881000
pali Loss On Issuance Of Preferred Stock
LossOnIssuanceOfPreferredStock
0
pali Loss On Issuance Of Secured Debt
LossOnIssuanceOfSecuredDebt
686000
pali Loss On Issuance Of Secured Debt
LossOnIssuanceOfSecuredDebt
0
pali Issuance Cost Allocated To Warrants
IssuanceCostAllocatedToWarrants
3247000
pali Issuance Cost Allocated To Warrants
IssuanceCostAllocatedToWarrants
0
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1544000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
0
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-122000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-102000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11718000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3220000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
3279000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
3333000
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
17939000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
pali Gain Loss From Change In Fair Value Of Share Liability
GainLossFromChangeInFairValueOfShareLiability
91000
pali Gain Loss From Change In Fair Value Of Share Liability
GainLossFromChangeInFairValueOfShareLiability
0
us-gaap Share Based Compensation
ShareBasedCompensation
1208000
us-gaap Share Based Compensation
ShareBasedCompensation
1544000
pali Accrued And Unpaid Interest
AccruedAndUnpaidInterest
0
pali Accrued And Unpaid Interest
AccruedAndUnpaidInterest
7000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
191000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
0
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-84000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
53000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1264000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-24000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2527000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1299000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-54000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
949000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
0
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
1250000
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
379000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
19900000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5209000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
99000
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
0
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
148000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25163000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
379000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
13391000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2846000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
739000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3623000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14130000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
777000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14104000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
751000
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
26000
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
26000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14130000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
777000
us-gaap Interest Paid Net
InterestPaidNet
61000
pali Equity Issuance Costs Included In Accounts Payable
EquityIssuanceCostsIncludedInAccountsPayable
67000
pali Equity Issuance Costs Included In Accounts Payable
EquityIssuanceCostsIncludedInAccountsPayable
0
pali Noncash Transaction Costs Shared With Acquiree
NoncashTransactionCostsSharedWithAcquiree
135000
pali Noncash Transaction Costs Shared With Acquiree
NoncashTransactionCostsSharedWithAcquiree
0
pali Acquisition Costs Related To Stock Issuance
AcquisitionCostsRelatedToStockIssuance
1184000
pali Acquisition Costs Related To Stock Issuance
AcquisitionCostsRelatedToStockIssuance
0
pali Issuance Of Common Stock To Former Shareholders Of Acquiree
IssuanceOfCommonStockToFormerShareholdersOfAcquiree
28728000
pali Issuance Of Common Stock To Former Shareholders Of Acquiree
IssuanceOfCommonStockToFormerShareholdersOfAcquiree
0
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
9503000
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0
pali Assets Assumed1
AssetsAssumed1
2000
pali Assets Assumed1
AssetsAssumed1
0
pali Acquisition Related Vesting Of Rsus Assumed In Merger
AcquisitionRelatedVestingOfRsusAssumedInMerger
41000
pali Acquisition Related Vesting Of Rsus Assumed In Merger
AcquisitionRelatedVestingOfRsusAssumedInMerger
0
pali Acquisition Related Fair Value Change In Warrant Liability Assumed In Merger
AcquisitionRelatedFairValueChangeInWarrantLiabilityAssumedInMerger
51000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-95700000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14100000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s financial statements and notes. The most significant estimates in the Company’s financial statements relate to clinical trial accruals and valuation of derivative liabilities and stock-based compensation. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.</span></p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2021Q3 pali Deferred Merger Transaction Costs
DeferredMergerTransactionCosts
0
CY2020Q4 pali Deferred Merger Transaction Costs
DeferredMergerTransactionCosts
1800000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions and in money market accounts, and at times balances may exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held nor has the Company experienced any losses in these accounts.</span></p>
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
8087000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-1843000
us-gaap Net Income Loss
NetIncomeLoss
-27689000
us-gaap Net Income Loss
NetIncomeLoss
-6078000
CY2021Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
-2969000
CY2020Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
5118000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1843000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-27689000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6078000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12100292
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2774502
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7902104
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2774237
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.42
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.50
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.19
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
8087000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-1843000
us-gaap Net Income Loss
NetIncomeLoss
-27689000
us-gaap Net Income Loss
NetIncomeLoss
-6078000
us-gaap Dilutive Securities
DilutiveSecurities
-5119000
CY2021Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
-2968000
CY2020Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
0
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
0
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
0
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
5119000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-1843000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-32808000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6078000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12100292
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2774502
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7902104
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2774237
CY2021Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
6479
CY2020Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7952998
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2774237
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
50894
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12106771
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2774502
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.42
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.19
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9290568
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1244584
CY2021Q2 pali Number Of Directors
NumberOfDirectors
8
CY2021Q3 pali Accrued Accounts Payable
AccruedAccountsPayable
346000
CY2020Q4 pali Accrued Accounts Payable
AccruedAccountsPayable
1018000
CY2021Q3 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
247000
CY2020Q4 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
875000
CY2021Q3 pali Accrued Director Stipends
AccruedDirectorStipends
102000
CY2020Q4 pali Accrued Director Stipends
AccruedDirectorStipends
759000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
27000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
88000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
722000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2740000
CY2021Q3 us-gaap Prepaid Insurance
PrepaidInsurance
1696000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
31000
CY2021Q3 pali Prepaid Expenses And Other Current Assets Other Receivables
PrepaidExpensesAndOtherCurrentAssetsOtherReceivables
116000
CY2021Q3 pali Prepaid Subscriptions And Fees
PrepaidSubscriptionsAndFees
97000
CY2020Q4 pali Prepaid Subscriptions And Fees
PrepaidSubscriptionsAndFees
35000
CY2021Q3 pali Prepaid Software Licenses
PrepaidSoftwareLicenses
36000
CY2020Q4 pali Prepaid Software Licenses
PrepaidSoftwareLicenses
0
CY2021Q3 pali Prepaid Expenses And Other Current Assets Deposits
PrepaidExpensesAndOtherCurrentAssetsDeposits
26000
CY2020Q4 pali Prepaid Expenses And Other Current Assets Deposits
PrepaidExpensesAndOtherCurrentAssetsDeposits
16000
CY2020Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
41000
CY2021Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
17000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1988000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
124000
CY2021Q3 us-gaap Warrants And Rights Outstanding Measurement Input
WarrantsAndRightsOutstandingMeasurementInput
3900000
pali Liability Classified Warrants
LiabilityClassifiedWarrants
0
CY2021Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
573000
CY2020Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
2719000
CY2021Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
5000
CY2020Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1578000
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
568000
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
1141000
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
568000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1047000
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
94000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
227000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
346000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
0
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
0
CY2021Q3 pali Long Term Debt Maturity Year Four And Thereafter
LongTermDebtMaturityYearFourAndThereafter
0
CY2021Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
573000
CY2021Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
5000
CY2021Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
0
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
568000
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
568000
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q3 pali Number Of Votes Per Share Of Common Stock
NumberOfVotesPerShareOfCommonStock
1
CY2021Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
8491007
CY2020Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
195712
CY2021Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
644138
CY2020Q4 pali Class Of Warrant Or Right Number Outstanding
ClassOfWarrantOrRightNumberOutstanding
195712
CY2020 pali Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
21.20
CY2020 pali Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife
P6Y7M6D
pali Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
7572191
pali Class Of Warrant Or Right Issued During Period Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice
4.03
pali Class Of Warrant Or Right Assumed During Period
ClassOfWarrantOrRightAssumedDuringPeriod
749792
pali Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
0
pali Class Of Warrant Or Right Settled During Period
ClassOfWarrantOrRightSettledDuringPeriod
20313
pali Class Of Warrant Or Right Forfeited Expired Or Cancelled During Period
ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod
6375
CY2021Q3 pali Class Of Warrant Or Right Number Outstanding
ClassOfWarrantOrRightNumberOutstanding
8491007
pali Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
5.64
pali Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife
P4Y8M23D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
32.72
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y5M26D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1541000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
59818
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
17.72
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
87025
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
799562
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
33.12
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
826769
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y4M20D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
799562
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
33.12
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y4M20D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
769332
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
33.20
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y3M29D
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.55
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
500000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
103000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
664000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1208000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1544000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P8Y2M4D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7605
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.800
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
153000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
275000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
158000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
280000
CY2020Q2 pali Rent Deferral Agreement Related To The Covid19 Pandemic Proration Of Deferred Balance Period
RentDeferralAgreementRelatedToTheCOVID19PandemicProrationOfDeferredBalancePeriod
P6M
CY2021Q3 pali Rent Deferral Agreement Related To The Covid19 Pandemic Deferred Balance
RentDeferralAgreementRelatedToTheCovid19PandemicDeferredBalance
0
CY2020Q4 pali Rent Deferral Agreement Related To The Covid19 Pandemic Deferred Balance
RentDeferralAgreementRelatedToTheCovid19PandemicDeferredBalance
87000
CY2020Q4 pali Accrual For Suspended Salary Benefits And Bonuses To Be Paid Upon Closing Of Merger
AccrualForSuspendedSalaryBenefitsAndBonusesToBePaidUponClosingOfMerger
1100000
CY2021Q3 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
102000
CY2020Q4 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
759000

Files In Submission

Name View Source Status
0000950170-21-004398-index-headers.html Edgar Link pending
0000950170-21-004398-index.html Edgar Link pending
0000950170-21-004398.txt Edgar Link pending
0000950170-21-004398-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img59125858_0.jpg Edgar Link pending
img59125858_1.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
pali-20210930.htm Edgar Link pending
pali-20210930.xsd Edgar Link pending
pali-20210930_cal.xml Edgar Link unprocessable
pali-20210930_def.xml Edgar Link unprocessable
pali-20210930_htm.xml Edgar Link completed
pali-20210930_lab.xml Edgar Link unprocessable
pali-20210930_pre.xml Edgar Link unprocessable
pali-ex31_1.htm Edgar Link pending
pali-ex31_2.htm Edgar Link pending
pali-ex32_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending